Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: MTP-101C; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infections
Interventions: Ceftaroline fosamil, Ceftriaxone plus vancomycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more

Conditions: Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions: VE800, Nivolumab, Vancomycin Oral Capsule; Biological · Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more

Conditions: Prosthetic Joint Infection, Vancomycin, Joint Diseases
Interventions: Experimental Intraosseous vancomycin 500mg in 250 mL NS, Standard IV administration of vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 19 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Periprosthetic Joint Infection
Interventions: REMEDY Spectrum IM Spacer Nail; Combination Product
Lead sponsor: OsteoRemedies, LLC; Industry
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Lansing, Michigan • Charlotte, North Carolina • Durham, North Carolina

Conditions: Infection, Closed Fractures
Interventions: Cefazolin, Vancomycin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 85 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more

Conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: Vancomycin, Neomycin and MTT capsules, Placebo capsules; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions: MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 4 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Colitis
Interventions: Vancomycin, Saline; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cystic Fibrosis
Interventions: Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Clostridium Difficile-associated Diarrhea (CDAD)
Interventions: Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Up to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more

Conditions: Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions: Bezlotoxumab, Standard CDI treatment; Biological · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Dietary Habits
Interventions: Ultra-processed Food Meal, Whole Food Meal; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Antibotics in Cementless Knees
Interventions: Tobramycin Powder, Vancomyscin; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infection
Interventions: Vancomycin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Total Knee Arthoplasty
Interventions: total knee arthroplasty, Tobramycin, Gentamicin, Antibiotic cement spacer; Procedure · Drug · Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bacterial Corneal Ulcer
Interventions: ProProKera Plus®; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Clostridioides Difficile Infection
Interventions: Ridinilazole, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 11 more

Conditions: Peanut Allergy
Interventions: Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT, Placebo plus placebo with PNOIT; Combination Product
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis, Colitis, Ulcerative
Interventions: VE202, Vancomycin Oral Capsule, VE202 Placebo, Vancomycin Placebo; Biological · Drug · Other
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Naples, Florida • Orlando, Florida • Decatur, Georgia + 6 more

Conditions: Ventilator Associated Pneumonia, Respiratory Infection, Tracheobronchitis
Interventions: aerosolized vancomycin or gentamicin; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Autism, Autism Spectrum Disorder
Interventions: Fecal Microbiota Transplant; Biological
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Ventura, California

Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Intestinal Microbiome Transplant in ALS

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

Study to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections

Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

Analysis of MicroBial Metabolites After Eating Refined Food

Intraarticular Antibiotic in TKA

Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

Antibiotic Loaded Cement After TKA

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

VE416 for Treatment of Food Allergy

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus